Draft Guidance On Lab-Produced Tests Being Misinterpreted – Gutman
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders have developed "misconceptions" regarding a recent draft guidance published by FDA on certain laboratory-developed assays, says Steve Gutman, director of the CDRH Office of In Vitro Diagnostic Device Evaluation & Safety
You may also be interested in...
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24
Regulatory News In Brief
Reprocessing rule: FDA Jan. 12 rescinds a Sept. 25, 2006, final rule that amended the validation data requirements for 52 types of reprocessed single-use devices, including catheter guide wires, oximeters and keratomes. The withdrawal is due to a "significant adverse comment" on the rule received from eye-care firm Alcon. FDA will reconsider the topic and propose a new regulation in the future...